Baclofen Role in Spasticity Management
Oral baclofen is useful for generalized spasticity but is limited by dose-dependent sedation and other side effects, while intrathecal baclofen should be reserved for severe spasticity refractory to oral agents or when side effects are intolerable.
Primary Indications
Baclofen is FDA-approved specifically for spasticity from multiple sclerosis and spinal cord diseases (injuries and other spinal cord pathologies), particularly for relief of flexor spasms, pain, clonus, and muscular rigidity 1.
Critical caveat: The FDA label explicitly states baclofen efficacy has not been established for stroke, cerebral palsy, or Parkinson's disease and is therefore not recommended for these conditions 1. This is important because stroke rehabilitation guidelines do discuss oral antispasticity agents, but the evidence base differs from the FDA-approved indications.
Treatment Algorithm by Severity
For Localized/Focal Spasticity
- First-line: Botulinum toxin injections are strongly recommended for focal upper limb spasticity (to improve range of motion, dressing, hygiene, positioning) and lower limb spasticity interfering with gait 2
- The 2025 VA/DoD guidelines note that botulinum toxin showed no significant difference from oral baclofen except for ankle spasticity, suggesting comparable efficacy 3
For Generalized Spasticity
- Oral baclofen can be useful but expect dose-limiting side effects in 25-75% of patients, including sedation, muscle weakness, nausea, and paresthesia 2, 4
- Typical oral dosing: 30-80 mg/day in divided doses, titrated to effect and tolerance 3
- Warning: Use caution when spasticity provides functional benefit for upright posture, balance, or locomotion 1
For Severe/Refractory Spasticity
- Intrathecal baclofen may be useful when patients fail to respond to maximum oral doses or experience intolerable side effects 2, 4
- Can be considered as early as 3-6 months after stroke onset for refractory cases 2
- A 2025 meta-analysis demonstrated significant spasticity reduction in both adults (mean difference -1.54 on Modified Ashworth Scale) and children (mean difference -0.70), with greater effectiveness for lower limb spasticity 5
- Intrathecal delivery bypasses the blood-brain barrier, optimizing efficacy while minimizing systemic side effects 4, 6
Mechanism and Clinical Effects
Baclofen works as a GABA-B receptor agonist, producing both presynaptic inhibition (reducing excitatory neurotransmitter release) and postsynaptic depression (activating G-protein-coupled potassium channels) in spinal ventral horn neurons 7. This dual mechanism explains its potent antispasticity effects at the spinal level.
Important Safety Considerations
- Additive CNS depression with alcohol and other CNS depressants 1
- Monitor patients with epilepsy closely, as seizure control may deteriorate 1
- Ovarian cysts occur in approximately 4% of patients on chronic therapy (vs 1-5% baseline rate) 1
- Not indicated for skeletal muscle spasm from rheumatic disorders 1
Emerging Evidence
Recent data suggest baclofen may have neuroprotective properties after spinal cord injury beyond its antispasticity effects, though this remains investigational 8.